The American Society of Clinical Oncology (ASCO) launched its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study in 2015. This session presents the IT platform used by TAPUR for determining patient eligibility for drugs and capturing patient outcomes.
Summarize the goals and process of ASCO’s TAPUR study
Explain how ASCO’s IT solution enables automated matching of patients to targeted drugs provided by TAPUR partners
Describe how the IT platform enables ASCO to collect structured patient outcome data
Recognize early successes at procuring targeted drugs for cancer patients in need